Instead of several other biotech companies, which have 1-2 products in early development stage, Epicept has several late stage development products: eg Ceplene, Lidopain NP1, LidoPAIN SP
Unfortunately Epicepts poor internet presence makes it nearly impossible for the public to realize the potential.
After EpiCept Completes Patient Enrollment in European Phase III Clinical Trial for LidoPain SP, it is to expect with the publication of good results next, because similar trials were already successfully finished in the past(US) and eg already licensed to Adolor.
Also, if you take the time, to hear the latest presentations and watch the online powerpoint presentations, you may reckon that several good news come up next.
This includes LidoPain SP trial results, Ceplene filing and so on...
As said, compared to other companies which has nothing but promises for some highly risk products, that may be on market in some years, Epicept has already several late stage products with high market potential and low development risks. So in my opinion, Epicept is totally undervaluated and so my recommendation is strong buy and hold.